Chemistry:UK-432,097
From HandWiki
| |
| Names | |
|---|---|
| Systematic IUPAC name
(12R,13R,14S,15S)-26-[(2,2-Diphenylethyl)amino]-N-ethyl-13,14-dihydroxy-3,8-dioxo-4,7,9-triaza-2(9,2)-purina-11(2)-pyridina-10(4,1)-piperidina-1(2)-oxolanaundecaphane-15-carboxamide | |
| Identifiers | |
3D model (JSmol)
|
|
| Abbreviations | UK-432,097 |
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C40H47N11O6 | |
| Molar mass | 777.887 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
UK-432,097 is a drug developed by Pfizer for the treatment of chronic obstructive pulmonary disease, which acts as a potent and selective agonist of the adenosine A2A receptor.[1] It was discontinued from clinical trials following poor efficacy results,[2] but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.[3]
References
- ↑ Russo, Cristina; Arcidiacono, Giuseppe; Polosa, Riccardo (2006). "Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma". Fundamental and Clinical Pharmacology 20 (1): 9–19. doi:10.1111/j.1472-8206.2005.00388.x. PMID 16448391.
- ↑ Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov
- ↑ "Structure of an Agonist-Bound Human A2A Adenosine Receptor". Science 332 (6027): 322–7. March 2011. doi:10.1126/science.1202793. PMID 21393508. Bibcode: 2011Sci...332..322X.
 |  |
